Walden Biosciences Announces Virtual Presentation at Canaccord Genuity 41st Annual Growth Conference

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Walden Biosciences, Inc. (Walden), a biotechnology company focused on transforming the treatment of kidney disease, today announced that Blaine McKee, Ph.D., President and CEO will be presenting at the 41^st Annual Canaccord Genuity Virtual Growth Conference. The presentation is scheduled for August 11, 2021 at 11:00am ET.

Walden is seeking to develop breakthrough medicines that reverse the progression of both rare and common forms of kidney disease and restore renal function. The Company believes that improving the function of podocytes – cells within the kidney that play an active role in the filtration process – represents the next frontier of renal medicine. Walden has active programs that address two novel targets for therapeutic intervention: soluble urokinase plasminogen activating receptor (suPAR) and dynamin. Targeting both suPAR and dynamin may be beneficial across numerous types of renal disease.

About Walden Biosciences

Walden Biosciences is a biotechnology company focused on transforming the treatment of kidney disease. Founded by world-renowned experts in renal disease, Walden is applying its unique, systems-based approach to address the intersection between the pathology and biology of kidney disease. Walden was launched in 2020 by ARCH Venture Partners and UCB Ventures and is headquartered in Cambridge, MA. For more information, please visit www.waldenbiosciences.com.

Contacts

FTI Consulting

Robert Stanislaro

[email protected]
-OR-

Helen O’Gorman

Helen.O’[email protected]